ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0977

The nuclear receptor DAX1 regulates WNT/β-catenin signaling to promote fibroblast activation and skin fibrosis in systemic sclerosis

Lichong Shen1, Xianyi Meng2, Yun Zhang3 and Joerg Distler4, 13Department of Rheumatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), 2Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Duesseldorf, Germany, 3University Hospital Duesseldorf, Duesseldorf, Germany, 4Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Duesseldorf, Germany

Meeting: ACR Convergence 2025

Keywords: Scleroderma, Systemic, transcription factor, Transforming Growth Factor (TGF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (0955–0977) Systemic Sclerosis & Related Disorders – Basic Science Poster I

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Nuclear receptors are a family of transcription factors that is commonly targeted for therapeutic intervention. Dosage-sensitive sex reversal adrenal hypoplasia congenital critical region on X chromosome gene 1, DAX1, also known as NR0B1, has been shown to regulate fundamental cellular processes. However, its role in fibrotic diseases has not been investigated so far. Here, we aimed to characterize the role of DAX1 in the pathogenesis of SSc.

Methods: Expression of DAX1 was analyzed by Western blot, imaging mass cytometry (IMC) and immunofluorescence. The effects of DAX1 knockdown or DAX1 antagonist BPK-29 on collagen production and myofibroblast differentiation were analyzed in cultured human fibroblasts, in bleomycin- and cGvHD-induced dermal fibrosis in mice, human 3D full-thickness skin equivalents and precision-cut human skin slices (PCSS). DAX1 signaling in TGFβ-stimulated fibroblasts was analyzed by RNASeq, co-immunoprecipitation and chromatin-immunoprecipitation.

Results: The expression of DAX1 was upregulated in SSc patients in a non-canonical TGFβ signaling dependent manner. DAX1 induced the activation of WNT/β-catenin signaling to drive fibroblast-to-myofibroblast transition. Knockout of DAX1 in murine skin by topical injection of DAX1-siRNA inhibited fibroblast-to-myofibroblast differentiation and ameliorated dermal fibrosis in two complementary mouse models of fibrosis. The selective DAX1 antagonist BPK-29 attenuated the TGFβ-induced myofibroblast activation or fibrotic tissue remodeling in cultured human dermal fibroblasts, and in three dimensional full-thickness skin equivalents. Moreover, inhibition of DAX1 ameliorated the expression of disease-relevant genes including WNT signaling in precision-cut slices of SSc skin. Mechanistically, DAX1 dimerized with E2F4 to promote WNT/β-catenin signaling via induction of WNT4 and WNT10B genes in cultured fibroblasts, in murine models of fibrosis and in precision-cut skin slices of SSc patients.

Conclusion: DAX1 is upregulated in SSc in a TGFβ-dependent manner to promote fibroblast activation via WNT/β-catenin signaling. Inactivation of DAX1 normalizes WNT/β-catenin signaling, inhibits fibroblast-to-myofibroblast transition and ameliorates experimental fibrosis. Targeting of DAX1 may thus offer potential for therapeutic intervention.


Disclosures: L. Shen: None; X. Meng: None; Y. Zhang: None; J. Distler: AstraZeneca, 2, Boehringer-Ingelheim, 2, 5, GlaxoSmithKlein(GSK), 2, Janssen, 2, Novartis, 2, Pfizer, 2, UCB, 2, 5.

To cite this abstract in AMA style:

Shen L, Meng X, Zhang Y, Distler J. The nuclear receptor DAX1 regulates WNT/β-catenin signaling to promote fibroblast activation and skin fibrosis in systemic sclerosis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/the-nuclear-receptor-dax1-regulates-wnt-%ce%b2-catenin-signaling-to-promote-fibroblast-activation-and-skin-fibrosis-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-nuclear-receptor-dax1-regulates-wnt-%ce%b2-catenin-signaling-to-promote-fibroblast-activation-and-skin-fibrosis-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology